These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32041299)

  • 1. Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.
    Aves KL; Goksøyr L; Sander AF
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32041299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Purification of Tag/Catcher AP205-Based Capsid Virus-Like Particle Vaccines.
    Aves KL; Sander AF
    Methods Mol Biol; 2024; 2720():127-141. PubMed ID: 37775662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
    Martinez FG; Zielke RA; Fougeroux CE; Li L; Sander AF; Sikora AE
    Infect Immun; 2023 Dec; 91(12):e0024523. PubMed ID: 37916806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.
    Brune KD; Leneghan DB; Brian IJ; Ishizuka AS; Bachmann MF; Draper SJ; Biswas S; Howarth M
    Sci Rep; 2016 Jan; 6():19234. PubMed ID: 26781591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana.
    Veerapen VP; van Zyl AR; Wigdorovitz A; Rybicki EP; Meyers AE
    Virus Res; 2018 Jan; 244():213-217. PubMed ID: 29196195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen.
    Tekewe A; Fan Y; Tan E; Middelberg AP; Lua LH
    Biotechnol Bioeng; 2017 Feb; 114(2):397-406. PubMed ID: 27497268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
    Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
    Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins.
    Walker A; Skamel C; Vorreiter J; Nassal M
    J Biol Chem; 2008 Nov; 283(48):33508-15. PubMed ID: 18826949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach.
    van Winkel CAJ; Moreno A; Curiel DT
    Mol Pharm; 2018 Dec; 15(12):5446-5453. PubMed ID: 30359030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.
    Janitzek CM; Carlsen PHR; Thrane S; Khanna VM; Jakob V; Barnier-Quer C; Collin N; Theander TG; Salanti A; Nielsen MA; Sander AF
    Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33562114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alphavirus capsid proteins self-assemble into core-like particles in insect cells: A promising platform for nanoparticle vaccine development.
    Hikke MC; Geertsema C; Wu V; Metz SW; van Lent JW; Vlak JM; Pijlman GP
    Biotechnol J; 2016 Feb; 11(2):266-73. PubMed ID: 26287127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
    Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines.
    Lei X; Cai X; Yang Y
    Expert Rev Vaccines; 2020 Mar; 19(3):235-246. PubMed ID: 32133886
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of capsid protein (p495) of hepatitis E virus expressed in Escherichia coli and assembling into particles in vitro.
    Zheng M; Jiang J; Zhang X; Wang N; Wang K; Li Q; Li T; Lin Q; Wang Y; Yu H; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2018 Apr; 36(16):2104-2111. PubMed ID: 29544686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).
    Zhang X; Wei M; Pan H; Lin Z; Wang K; Weng Z; Zhu Y; Xin L; Zhang J; Li S; Xia N; Zhao Q
    Vaccine; 2014 Jul; 32(32):4039-50. PubMed ID: 24892250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient application of a baculovirus-silkworm larvae expression system for obtaining porcine circovirus type 2 virus-like particles for a vaccine.
    He Q; Cao Z; Wang P; Lu Q; Zheng H; Sun J
    Arch Virol; 2020 Oct; 165(10):2301-2309. PubMed ID: 32757056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display.
    Koho T; Ihalainen TO; Stark M; Uusi-Kerttula H; Wieneke R; Rahikainen R; Blazevic V; Marjomäki V; Tampé R; Kulomaa MS; Hytönen VP
    Eur J Pharm Biopharm; 2015 Oct; 96():22-31. PubMed ID: 26170162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines.
    Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM
    Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.